[{"address1": "900 North Point Parkway", "address2": "Suite 200", "city": "Alpharetta", "state": "GA", "zip": "30005", "country": "United States", "phone": "678 270 3631", "fax": "678 270 4033", "website": "https://clearsidebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.", "age": 71, "title": "President, CEO & Director", "yearBorn": 1952, "fiscalYear": 2022, "totalPay": 816400, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles A. Deignan", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 536950, "exercisedValue": 0, "unexercisedValue": 24545}, {"maxAge": 1, "name": "Dr. Thomas A. Ciulla M.B.A., M.D.", "age": 58, "title": "Chairman of Scientific Advisory Board", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 597205, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Kobin", "age": 56, "title": "Head of Investor Relations", "yearBorn": 1967, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick  McElheny", "title": "Vice President of Corporate Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rafael V. Andino", "age": 58, "title": "Senior Vice President of Engineering & Manufacturing", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan L. Coultas Ph.D.", "title": "Chief Clinical Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Hang  Chong M.B.A., M.D.", "title": "Chief Medical Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leslie B. Zacks", "age": 54, "title": "Secretary", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.73, "open": 1.71, "dayLow": 1.63, "dayHigh": 1.76, "regularMarketPreviousClose": 1.73, "regularMarketOpen": 1.71, "regularMarketDayLow": 1.63, "regularMarketDayHigh": 1.76, "beta": 2.286, "forwardPE": -2.9137933, "volume": 201641, "regularMarketVolume": 201641, "averageVolume": 348526, "averageVolume10days": 527980, "averageDailyVolume10Day": 527980, "bid": 1.64, "ask": 1.71, "bidSize": 100, "askSize": 100, "marketCap": 126278672, "fiftyTwoWeekLow": 0.65, "fiftyTwoWeekHigh": 2.12, "priceToSalesTrailing12Months": 15.351164, "fiftyDayAverage": 1.4341, "twoHundredDayAverage": 1.13573, "currency": "USD", "enterpriseValue": 140359728, "floatShares": 69246321, "sharesOutstanding": 74721104, "sharesShort": 275405, "sharesShortPriorMonth": 183923, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0037, "heldPercentInsiders": 0.07165, "heldPercentInstitutions": 0.21234, "shortRatio": 2.03, "shortPercentOfFloat": 0.0039, "impliedSharesOutstanding": 74721104, "bookValue": -0.253, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -32485000, "trailingEps": -0.53, "forwardEps": -0.58, "enterpriseToRevenue": 17.063, "enterpriseToEbitda": -5.665, "52WeekChange": 0.7604166, "SandP52WeekChange": 0.29191303, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CLSD", "underlyingSymbol": "CLSD", "shortName": "Clearside Biomedical, Inc.", "longName": "Clearside Biomedical, Inc.", "firstTradeDateEpochUtc": 1464874200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ea57bdfa-5d41-3e30-b431-13e72798980d", "messageBoardId": "finmb_145617165", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.69, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.5, "targetMedianPrice": 5.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 28920000, "totalCashPerShare": 0.387, "ebitda": -24777000, "totalDebt": 43001000, "quickRatio": 4.27, "currentRatio": 4.421, "totalRevenue": 8226000, "revenuePerShare": 0.133, "returnOnAssets": -0.36398, "freeCashflow": -17930500, "operatingCashflow": -18135000, "revenueGrowth": 18.227, "grossMargins": 0.95684, "operatingMargins": -0.45942003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-27"}]